Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $10.45 and last traded at $9.80, with a volume of 1097190 shares trading hands. The stock had previously closed at $9.24.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on AVXL. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research note on Monday, November 4th. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a "strong-buy" rating in a research report on Monday, July 22nd.
Get Our Latest Stock Analysis on Anavex Life Sciences
Anavex Life Sciences Stock Performance
The firm's fifty day simple moving average is $5.83 and its 200-day simple moving average is $5.25. The stock has a market cap of $775.92 million, a P/E ratio of -18.30 and a beta of 0.60.
Hedge Funds Weigh In On Anavex Life Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in shares of Anavex Life Sciences during the third quarter worth $134,000. Atria Investments Inc purchased a new position in Anavex Life Sciences during the 3rd quarter valued at about $76,000. Balentine LLC bought a new stake in shares of Anavex Life Sciences in the 3rd quarter valued at about $115,000. Forum Financial Management LP acquired a new stake in Anavex Life Sciences in the 3rd quarter worth approximately $200,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Anavex Life Sciences by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 6,366 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company's stock.
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Read More
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
